REGN Feb 2025 1200.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 02:22PM EDT
| Previous close | 104.95 |
| Open | 104.95 |
| Bid | 64.90 |
| Ask | 73.00 |
| Strike | 1,200.00 |
| Expiry date | 2025-02-21 |
| Day's range | 104.95 - 104.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
GuruFocus.comInsider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), executed a sale of 100 shares of the company at a price of $1178.69 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 17,682 shares of Regeneron Pharmaceuticals Inc.
ZacksMerck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
ZacksBiotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
© 2024 Yahoo. All rights reserved.